Boston, MA 05/08/2014 (wallstreetpr) – Boston Scientific Corporation (NYSE:BSX) has entered in a definitive agreement to get IoGyn, Inc. The deal will close within few days. IoGyn is a pre-commercial stage company who has the unique, innovative technology found effective in treating Intrauterine Fibroids and Polyps. It has already got the FDA approval. The technology is known as the Symphion™ System.
The acquisition of new innovation
The new acquisition cannot be simply termed as the acquisition of a pre-commercial stage company. It is the pairing of the new innovative Symphion System with another system of BSX known as Boston Scientific Genesys HTA™ System. The pairing will result in a strong association to treat the abnormal uterine bleeding. It will help Boston Scientific Corporation (NYSE:BSX) to manufacture a new and effective set of gynecologic surgery products.
Broadens the existing portfolio
Symphion system is the nest generation system. It assists in the hysteroscopic intrauterine tissue removal. It will act as a strong means to broaden the Boston Scientific portfolio. The portfolio talked here includes the minimally-invasive approaches used to treat debilitating gynecologic conditions. It is a very severe problem affecting millions of women worldwide. The Symphion system is very effective in restricting the growth within the uterus. It can then eliminate the harmed tissue through the innovative fluid management system.
The brighter horizons
Talking about the other alternative approaches, they have not been able to show any positive results. In fact, they have worsened the problem. The Symphion System is an effective way to treat fibroids and polyps. It is safer than other alternative forms of treatment. The invasive procedures used are minimal. There are no cases reported of sarcoma due to the treatment. It also doesn’t have any negative impact on the women’s ability to have children. As of now, Boston Scientific Corporation (NYSE:BSX) estimates the hysteroscopic market segment at $80 million. It is expected to cross $200 million by 2020.
